Durvalumab Plus Tremelimumab In Patients With Grade 3 Neuroendocrine Neoplasms Of Gastroenteropancreatic Origin: Updated Results From The Multicenter Phase Ii Dune Trial (Getne 1601)

J. Capdevila,S. Landolfi, J. Hernando, A. Teule, R. Garcia-Carbonero, A. Custodio, A. Cubillo, T. Alonso-Gordoa,A. Carmona-Bayonas,G. Crespo,M. Blanco,A. Viudez,A. La Casta, I. Sevilla,A. Segura,C. Lopez,M. Benavent Vinuales,P. Nuciforo, J. L. Manzano

ANNALS OF ONCOLOGY(2021)

引用 2|浏览7
暂无评分
AI 理解论文
溯源树
样例
生成溯源树,研究论文发展脉络
Chat Paper
正在生成论文摘要